Assessing treatment effectiveness of the ‘Repurposing-Drugs-in-Oncology’ (ReDO) protocol for cancer: The ReDO cancer treatment study (ACTRN12623001164684) (2023)

Government Record · Dr Taufiq Binjemain, Willow Vale Clinic, Queensland, Australia · November 9, 2023

Dr Taufiq Binjemain et al., 2023-11-09: Australian single-group case-series registration for a 19-item repurposing protocol that includes ivermectin 25 mg nightly, with circulating tumour cell count as the primary endpoint; 50 patients planned, recruiting.

10 Ivermectin 25 mg/night

Dr Taufiq Binjemain et al., 2023-11-09: Australian single-group case-series registration for a 19-item repurposing protocol that includes ivermectin 25 mg nightly, with circulating tumour cell count as the primary endpoint; 50 patients planned, recruiting. C1 record field (transcribed from the ICTRP bridged record; primary register page https://anzctr.org.au/ACTRN12623001164684.aspx). Australia; interventional, non-randomised, single group, open label; target 50; first enrolment 2025-02-05; recruiting as of ICTRP refresh 2026-01-05. Full protocol list as registered: dichloroacetate 500 mg x2, propranolol 40 mg x2, metformin 500 mg, atorvastatin 20 mg, sodium phenylbutyrate 1-4 g, dipyridamole 100-200 mg x2, hydroxychloroquine 200 mg, ivermectin 25 mg/night, melatonin 100 mg, doxycycline 50 mg x2, mebendazole/fenbendazole 100 mg x2, loratadine 20 mg x2, plus genistein, D-mannose, vitamin A, berberine, EGCG, hydroxycitrate, Nigella sativa oil; items introduced one at a time 3 days apart over 2 months then continued 90 days. PRIMARY OUTCOME is circulating tumour cell count (ISET/Rarecells), not survival. Registered, no results. Registry entry; no results posted. Study type: regulatory record.